Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

679
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
679

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A hERG Blocker Facilitates K<sup>+</sup> Channel Current by Agonizing Pore Opening while Blocking.

bioRxiv : the preprint server for biology·2026
Same author

Author Correction: De novo design of quasisymmetric two-component protein cages.

Nature·2026
Same author

De novo design of miniproteins targeting GPCRs.

Nature·2026
Same author

Mitochondria-Targeting Moieties Based on N-Tethered Pyridinium Cations.

Angewandte Chemie (International ed. in English)·2026
Same author

MotifLeadDB: A Hierarchical Structural Data Set for Congeneric Ligand Binding Activity Change.

Journal of chemical information and modeling·2026
Same author

De novo design of quasisymmetric two-component protein cages.

Nature·2026

相关实验视频

Updated: Jun 14, 2025

Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions
12:30

Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions

Published on: March 5, 2012

21.6K

一个人工智能加速虚拟选平台用于药物发现.

Guangfeng Zhou1,2, Domnita-Valeria Rusnac3, Hahnbeom Park4,5

  • 1Department of Biochemistry, University of Washington, Seattle, WA, USA.

Nature communications
|September 5, 2024
PubMed
概括

罗塞塔VS通过准确预测大型化合物库的分子相互作用来增强药物发现. 这种由人工智能驱动的平台快速识别出具有高结合性亲缘关系的有希望的药物线索.

更多相关视频

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

5.1K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K

相关实验视频

Last Updated: Jun 14, 2025

Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions
12:30

Avidity-based Extracellular Interaction Screening AVEXIS for the Scalable Detection of Low-affinity Extracellular Receptor-Ligand Interactions

Published on: March 5, 2012

21.6K
Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

5.1K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K

科学领域:

  • 计算化学和药物发现
  • 结构生物学是结构生物学.
  • 药理学中的人工智能

背景情况:

  • 基于结构的虚拟查 (SBVS) 对于识别候选药物至关重要.
  • 准确预测结合姿势和亲和力对于SBVS成功至关重要.
  • 当前的方法面临着巨大的化学库和受体灵活性所带来的挑战.

研究的目的:

  • 开发一种高度准确的SBVS方法,RosettaVS,用于预测对接姿势和结合亲和力.
  • 为大规模虚拟选创建一个开源,AI加速的平台.
  • 为了识别针对治疗点KLHDC2和NaV的新型打击化合物1.7.7.

主要方法:

  • 开发了RosettaVS,一种基于结构的先进虚拟选方法.
  • 将受体灵活性建模纳入选方法.
  • 利用人工智能加速平台对数十亿个复合库进行选,以对抗KLHDC2和NaV1.7.7.

主要成果:

  • 罗塞塔VS在基准测试上表现优于最先进的方法.
  • 确定了KLHDC2的7个命中化合物 (14%的命中率) 和NaV的4个命中率 (44%的命中率) 1.7.7.
  • 所有已识别的热点均表现出单位的微分子结合亲缘关系,并且在不到七天内被发现.

结论:

  • 由人工智能加速的RosettaVS平台能够快速准确地对庞大的复合库进行虚拟选.
  • 该方法成功地确定了用于具有挑战性的目标的新化合物.
  • X射线结晶学验证了KLHDC2联体的预测结合姿势,证实了该方法在发现方面的有效性.